Japanese Building Stock News

Advantest (TSE:6857) has announced euro-denominated convertible bonds due 2031, targeting a total issue size of ¥100b. The company plans to use the proceeds to expand semiconductor test equipment production, secure key inventory, and accelerate development of next generation solutions. The bonds come with a 60% conversion premium, with management highlighting an aim to limit shareholder dilution while raising growth capital. Advantest’s new funding plan follows a 1-year share price gain of...

JX Advanced Metals (TSE:5016) is taking part in a private placement for Fireweed Metals, securing an equity position in the company. The funding supports Fireweed Metals' mining projects in Canada focused on critical minerals. The transaction includes participation alongside other industry players involved in multiple large mining developments. For JX Advanced Metals, known for its materials and metals operations, this move extends its reach into Canadian critical mineral projects at a time...

As global markets navigate the complexities of Middle East tensions and energy market volatility, major U.S. stock indexes have ended a turbulent week higher, with smaller-cap indexes also showing solid gains. In this environment, high-growth tech stocks continue to capture investor attention as they offer potential for significant returns amidst geopolitical and economic shifts.

In a global market environment characterized by geopolitical tensions and energy market volatility, investors are seeing major U.S. stock indexes rally amid signs of potential de-escalation in the Middle East. As markets navigate these uncertainties, identifying stocks trading below their intrinsic value can provide opportunities for those looking to capitalize on potential undervaluation in sectors resilient to current economic shifts.

In March 2026, Chugai Pharmaceutical reported that partner Roche would discontinue clinical development of GYM329 (emugrobart) for spinal muscular atrophy and facioscapulohumeral muscular dystrophy after Phase II/III data showed insufficient functional benefit despite good safety and target engagement. An important nuance for investors is that while these neuromuscular programs are ending, Roche and Chugai are continuing Phase II development of emugrobart in obesity, where the biological and...

Mitsui O.S.K. Lines held a board meeting on March 31, 2026 to discuss Phase 2 of its corporate management plan “BLUE ACTION 2035,” while major shareholder Elliott Investment Management publicly argued that the current medium-term plan does not sufficiently address shareholder returns or large unrealized gains on the balance sheet. This tension between long-term corporate planning and calls from an activist investor to confront perceived undervaluation puts Mitsui O.S.K. Lines’ capital...

Mitsubishi Corporation (Americas) is joining JETRO's first official business delegation to eMerge Americas 2026. The company will explore collaboration opportunities with U.S. startups through reverse pitch and networking sessions. This participation connects Mitsubishi (TSE:8058) with early stage technology and potential cross border partnerships in the U.S. market. Mitsubishi (TSE:8058) enters this delegation with a share price of ¥5,397.0 and a 5 year return of more than 5x. The stock...

Mitsubishi HC Capital Inc. recently entered into a capital and business alliance with DENZAI K.K., a lifting engineering company specializing in large cranes and heavy-load transport for infrastructure projects in Japan and overseas. This partnership is unusual in that it tightly links financial leasing capabilities with deep operational expertise in critical infrastructure assets, aiming to unlock new business models around heavy machinery usage and maintenance. We’ll now explore how this...

Recent share performance and business mix Sony Group (TSE:6758) has seen mixed recent returns, with the share price roughly flat over the past year and a decline in the past 3 months, despite positive multi year total returns. Over the past month the stock has posted a small decline, following a modest gain over the past week. Year to date performance is negative, even as 3 year and 5 year total returns remain well above current levels. The group reports annual revenue of ¥13.2b and net...

Wondering whether Furukawa Electric's share price matches its underlying value, or if the story has run ahead of the fundamentals? The stock last closed at ¥32,420, with returns of 0.7% over 7 days, 10.9% over 30 days and 207.6% year to date, while the 1 year and 3 year returns are very large in absolute terms. These moves sit against a backdrop of ongoing attention around the company and the wider electrical equipment space, with investors closely watching how capital spending trends and...

OYO Corporation's ( TSE:9755 ) robust earnings report didn't manage to move the market for its stock. We did some...

Soft earnings didn't appear to concern Resonac Holdings Corporation's ( TSE:4004 ) shareholders over the last week. We...

Investors were disappointed by Cookpad Inc.'s ( TSE:2193 ) latest earnings release. Our analysis has found some reasons...

If you are wondering whether Takeda Pharmaceutical's current share price lines up with its underlying worth, this breakdown is aimed squarely at you. The stock last closed at ¥5,890, with returns of 1.7% over 7 days, 2.8% over 30 days, 19.8% year to date, 35.0% over 1 year, 52.0% over 3 years, and 98.2% over 5 years, which gives plenty of recent performance data to weigh against valuation. Recent news coverage has focused on Takeda Pharmaceutical's position in the pharmaceutical sector and...

In March 2026, Recruit Holdings Co., Ltd. announced a share repurchase program of up to 64,000,000 shares, or 4.58% of outstanding shares (excluding treasury stock), with a budget of ¥350,000 million and potential uses ranging from employee compensation and M&A consideration to possible cancellation, running through November 30, 2026. The board’s parallel move to consider cancelling a portion of its ¥167,698,699 shares in treasury highlights a sharpened focus on capital efficiency and...

SoftBank Group stock performance snapshot SoftBank Group (TSE:9984) has drawn attention after a period of mixed share performance, with recent returns over the month and past 3 months contrasting with a much stronger 1 year and 3 year total return profile. See our latest analysis for SoftBank Group. Recent share price moves have been weak, with a 1 day share price return of a 4.54% decline and a 30 day share price return of a 9.99% decline. However, the 1 year total shareholder return of...

Star Mica Holdings (TSE:2975) opened Q1 2026 with revenue of ¥21.3 billion and basic EPS of ¥71.37, against a backdrop of trailing twelve month EPS of ¥153.17 and revenue of ¥74.37 billion that has been expanding alongside a 35.4% earnings growth figure over the past year and an 11.6% per year five year average. Over recent quarters, the company has seen revenue move from ¥15.22 billion in Q4 2024 through ¥16.09 billion in Q1 2025 and ¥20.62 billion in Q4 2025 to ¥21.3 billion in Q1 2026...

In the first quarter of 2026, Hamamatsu Photonics K.K. completed a board-approved buyback of 7,662,800 shares for ¥13,010.92 million, while Sakura Finetek and Hamamatsu announced an alliance to create a seamless workflow from tissue preparation to digital pathology imaging. Together, these moves highlight Hamamatsu’s focus on integrating its imaging technology into clinical diagnostics workflows while actively returning capital to shareholders through repurchases. We’ll now examine how...

On March 24, 2026, Oriental Land Co., Ltd. approved the establishment of wholly owned subsidiary ORIENTAL LAND CRUISE CO., LTD. to manage and operate Japan-based Disney cruise services, with operations planned to begin in Japanese fiscal year 2028. This move extends Oriental Land’s business beyond Tokyo Disney Resort®, aligning with its 2035 Long-term Management Strategy to build a more diversified leisure portfolio centered on cruise operations. With the new cruise subsidiary set to run...

Calliditas Therapeutics AB, an Asahi Kasei company, has recently announced that new Phase 3 NefIgArd study data in primary immunoglobulin A nephropathy (IgAN) will be presented at the 2026 World Congress of Nephrology in Yokohama, Japan, including secondary, biomarker, and mechanistic analyses of its gut-targeted therapy Nefecon. This extensive dataset, spanning seven scientific posters and a dedicated symposium on the evolving IgAN treatment paradigm, underscores Asahi Kasei’s growing...

Investors may be wondering if Sumitomo at ¥6,182 is still priced fairly after such a strong run, or if the current share price is getting ahead of itself. The stock has returned 6.0% over the last 7 days, a 6.4% decline over 30 days, 11.0% year to date and 88.1% over the last year, along with a very large 3 year gain and 386.0% over 5 years that naturally raises questions about value. Recent coverage has focused on Sumitomo's position in the capital goods sector and how investors are...

ITOCHU (TSE:8001) has moved to expand in e-waste recycling, teaming up with ERI to co-own ERI Japan, a 50-50 venture that brings ERI’s IT asset disposition services into the Japanese market. See our latest analysis for ITOCHU. At a share price of ¥2,070.0, ITOCHU’s 1 day share price return of 4.84% contrasts with a 30 day share price decline of 7.20%. A 1 year total shareholder return of 54.43% and 5 year total shareholder return of 231.72% point to strong longer term compounding despite...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Rorze (TSE:6323) is back in focus after revising its fiscal 2026 earnings guidance, as an extraordinary loss tied to a jury verdict and litigation provision reshapes expected profit attributable to shareholders. See our latest analysis for Rorze. The guidance cut linked to litigation arrives after a choppy period for the shares, with a 30 day share price return of a 13.88% decline, a 90 day share price return of 21.40%, and a 1 year total shareholder return of 92.73%. This suggests that...